or the body’s own cells or tissues. The term “tolerogenic” refers to the immune system’s selective tolerance of a specific pathogenic or immune activating antigen following treatment with Idogen’s therapy. Idogen’s intention is to revolutionise the treatment of several disorders in which the body’s immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

Idogen’s most advanced product candidate, IDO 8, is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII).

The company also develops IDO T – a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection. IDO T is expected to reduce the need for immunosuppressive drugs and improve transplant survival, thereby reducing the risk of cancer and infections.